identifying and prioritizing genetically validated drug targets
Central to these initiatives is COMPASS, our proprietary, purpose-built platform that combines human genetic data, functional genomic tools and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression to create next-generation precision medicines.
The application of COMPASS assists in three core areas: target identification, drug discovery and drug development. For target identification, COMPASS allows us to prioritize, validate and reduce development risk of drug targets. For drug discovery, it aids in determining how best to drug the identified target and assists in estimating therapeutic effect size. For drug development, COMPASS helps to identify biomarkers and patient enrichment strategies, and provides insights about therapeutic window and tolerability.
We purposely built COMPASS to take advantage of these three disciplines to unlock the central tenet of precision medicine: deliver the right drug, to the right patient, at the right time.
By employing COMPASS, and its integration with our extensive drug discovery capabilities, we believe we can accelerate the pace of therapeutic development as well as increase the likelihood of producing therapies that provide meaningful clinical benefit. At Maze, we have leveraged COMPASS to build a broad pipeline of product candidates, including some that we are advancing ourselves and some that are partnered with external collaborators.
We are initially pursuing programs based on genetic insights in metabolic, cardiovascular and renal diseases, as well as neurological and ophthalmic disorders.